Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis.

Front Immunol · 2025 · PMC12043626 · PMID 40313945

Europe PMC DOI

hedged sentence

0.1060

closest p · 2.1× alpha

0.1060

boldest claim

The sentences

did not reach statistical significancep = 0.106not close (p > 0.1)

Although the QMG score in the worse group decreased from 13.5 ± 4.1 to 7.0 (5.0, 13.8), this reduction did not reach statistical significance (p = 0.106), which may be attributed to the small sample size.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.